AXIS MATRIX / FOUR FIELD NOTES
Four Signals. Two Doorways. Unequal Evidence.
A side-by-side read of what changes when receptor route, molecular duration, population, and endpoint change.
The short version: same axis, unequal evidence
These four peptides can all increase growth-hormone signaling, but they are not interchangeable. Sermorelin, tesamorelin, and CJC-1295 activate the GHRH receptor, the pituitary’s native upstream instruction. Ipamorelin activates the ghrelin receptor, a separate doorway into GH release that also touches appetite and gut biology.
The largest differences are duration and evidence maturity. Sermorelin is a short active GHRH fragment with small human studies. Tesamorelin is a stabilized analogue with an approved indication and randomized trials in HIV-associated abdominal fat accumulation [8][9]. CJC-1295 DAC was engineered for multi-day exposure, but its human record is early pharmacology rather than clinical outcomes [15][16]. Ipamorelin has acute human pharmacology, animal findings, and a postoperative Phase 2 trial that missed its primary endpoint [19][20]. The comparison does not identify a “best” peptide. It identifies which question each molecule can answer—and which conclusions the evidence cannot carry.
The axis matrix
| Dimension | Sermorelin | Tesamorelin | CJC-1295 | Ipamorelin |
|---|---|---|---|---|
| Primary receptor | GHRH receptor | GHRH receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Design idea | Active GHRH fragment | Stabilized full-length GHRH analogue | Stabilized analogue; DAC form binds albumin | Selective small GHRP |
| Signal profile | Shorter upstream stimulus | Stabilized, pulsatile endogenous GH stimulus | Multi-day with DAC; shorter without DAC | Short GH pulse in human PK work [20] |
| Best-supported research setting | Pituitary response, pediatric deficiency, small older-adult studies [5][7] | HIV-associated abdominal fat accumulation [8][10][12] | Healthy-adult GH/IGF-1 pharmacology [15][16] | Acute PK and postoperative proof-of-concept; primary endpoint missed [19][20] |
| Evidence maturity | Human studies, limited aging outcomes | Approved narrow indication and pooled RCTs [8][9] | Early human studies; no established clinical outcome | Sparse human evidence; animal work remains prominent [17][21] |
| Defining caveat | Anti-aging claims outrun outcomes [3] | Specific population cannot be generalized | DAC/no-DAC confusion and prolonged exposure | Different receptor, appetite biology, no long-term human record |
Mechanism: three GHRH keys and one ghrelin key
The three GHRH analogues speak the pituitary’s usual upstream language. Sermorelin supplies the shortest fully active GHRH fragment. Tesamorelin modifies the longer hormone for stability. CJC-1295 adds substitutions and, in its DAC version, an albumin-binding strategy that dramatically extends persistence. The receptor is shared; molecule lifetime and clinical development are not.
Ipamorelin instead activates GHS-R1a. Its human pharmacology produced a discrete GH pulse with an approximately two-hour terminal half-life [20]. That route may complement GHRH signaling in theory, but this corpus contains no controlled outcomes trial of a CJC-1295–ipamorelin combination. Separate mechanisms do not constitute combination evidence.
All four ultimately connect to GH and downstream IGF-1, so common issues—growth signaling, fluid handling, and glucose regulation—remain relevant. Receptor selectivity and preserved pulsatility can refine a safety hypothesis. They cannot establish long-term safety without long-term data.
Evidence maturity: indication, biomarker, or animal model?
Tesamorelin stands apart because its studies connect mechanism to a defined clinical outcome in a defined population. A pooled analysis of five randomized trials found reductions in visceral and hepatic fat measures in HIV-associated lipodystrophy [8]. A drug-safety monograph documents its approved indication [9]. This is mature evidence, bounded by population and purpose.
Sermorelin’s record demonstrates pituitary responsiveness. Studies show GH release in healthy men, growth effects in children with deficiency, and short-term axis restoration in a small older-men comparison [5][6][7]. Those are human data, but the aging-outcome claim remains unproven; the published editorial caution is direct [3].
CJC-1295’s record is pharmacological. Human studies quantify extended GH/IGF-1 elevation and preserved pulses [15][16]. Ipamorelin’s evidence is thinner: acute human PK, a negative postoperative efficacy result, and animal studies [17][19][20][21]. A useful comparison asks what kind of endpoint was measured before it asks how exciting the result sounds.
What somatopause research can—and cannot—ask
The age-related decline frame makes sermorelin the natural lead because it tests whether an older pituitary can still answer a GHRH signal. The small older-men study suggests it can, at least over a short experimental window [7]. That result makes GH-axis plasticity an interesting research question.
It does not make “restoring youthful levels” a validated health goal. Aging changes many interlocking systems, and raising one endocrine marker may bring tradeoffs as well as possible benefits. The editorial literature warns against treating secretagogues as established anti-aging interventions [3]. Tesamorelin shows that a GHRH analogue can have a validated use, but in HIV-associated fat redistribution—not aging generally [8][9]. CJC-1295 and ipamorelin add design and receptor questions while adding uncertainty.
The disciplined conclusion is modest: the axis remains responsive, molecule design changes the time course, and evidence maturity varies sharply. Outcomes, populations, and safety windows matter more than a shared category label.
How to read a peptide comparison responsibly
First, separate receptor from result. Two compounds that raise GH may differ in appetite signaling, persistence, feedback, and studied population. Second, separate biomarkers from outcomes. GH and IGF-1 changes show target engagement; they do not by themselves show better sleep, recovery, body composition, or lifespan. Third, separate human trials from animal models. Ipamorelin’s ferret and rat findings are legitimate preclinical observations, not clinical proof [17][21].
Finally, treat missing evidence as missing. CJC-1295’s impressive duration numbers [15] do not fill the long-term outcomes gap. Ipamorelin’s short postoperative safety window [19] does not settle chronic safety. Tesamorelin’s indication-specific results [8][10][12] do not generalize automatically. This is why the matrix is a map rather than a verdict.